| Item type |
学術雑誌論文 / Journal Article_02(1) |
| 公開日 |
2025-06-20 |
| タイトル |
|
|
タイトル |
Regression of cutaneous squamous cell carcinoma after the development of pembrolizumab-induced bullous pemphigoid |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
bullous pemphigoid |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
immune checkpoint inhibitor |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
pembrolizumab |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
skin |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
treatment |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Shin, Iinuma
Kei, Hayashi
Akemi, Ishida-Yamamoto
|
| bibliographic_information |
JEADV Clinical Practice
巻 2,
号 1,
p. 136-139,
発行日 2022-11-01
|
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2768-6566 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1002/jvc2.77 |
| リンクURL |
|
|
内容記述タイプ |
Other |
|
内容記述 |
https://onlinelibrary.wiley.com/doi/10.1002/jvc2.77 |
|
言語 |
en |
| item_5_description_33 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Bullous pemphigoid is a rare complication of immune checkpoint inhibitor treatment. We report a case of pembrolizumab-induced bullous pemphigoid in a patient with malignant melanoma and concomitant cutaneous squamous cell carcinoma that regressed. A 77-year-old woman with metastatic malignant melanoma and a 3-year history of a growing skin nodule on her left calf was treated with pembrolizumab. Histopathological examination of the skin nodule established the diagnosis of cutaneous squamous cell carcinoma. Seven months after the initiation of pembrolizumab treatment, the patient developed bullous pemphigoid. Discontinuation of pembrolizumab and initiation of oral prednisolone resulted in the resolution of the skin blisters. Additionally, complete response of the metastatic malignant melanoma was noted after pembrolizumab treatment. Furthermore, the cutaneous squamous cell carcinoma completely resolved after the development of bullous pemphigoid. This case supports the hypothesis that the development of bullous pemphigoid is indicative of a sufficient antitumor response after immunotherapy. |
|
言語 |
en |
| 注記 |
|
|
内容記述タイプ |
Other |
|
注記 |
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
| item_5_textarea_42 |
|
|
|
en |
|
|
© 2022 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. |
2025062001.pdf (7.7 MB)
.png)
